Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab
Leena George,1 Adam Wright,1 Vijay Mistry,1 Amanda Sutcliffe,1 Latifa Chachi,1 Koirobi Haldar,1 Mohammadali Yavari Ramsheh,1 Matthew Richardson,1 René van der Merwe,2 Ubaldo Martin,3 Paul Newbold,3 Christopher E Brightling11Department of Respiratory Sciences, Institute for Lung Health, Na...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-06-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/sputum-streptococcus-pneumoniae-is-reduced-in-copd-following-treatment-peer-reviewed-article-COPD |
| _version_ | 1831809810723504128 |
|---|---|
| author | George L Wright A Mistry V Sutcliffe A Chachi L Haldar K Ramsheh MY Richardson M van der Merwe R Martin U Newbold P Brightling CE |
| author_facet | George L Wright A Mistry V Sutcliffe A Chachi L Haldar K Ramsheh MY Richardson M van der Merwe R Martin U Newbold P Brightling CE |
| author_sort | George L |
| collection | DOAJ |
| description | Leena George,1 Adam Wright,1 Vijay Mistry,1 Amanda Sutcliffe,1 Latifa Chachi,1 Koirobi Haldar,1 Mohammadali Yavari Ramsheh,1 Matthew Richardson,1 René van der Merwe,2 Ubaldo Martin,3 Paul Newbold,3 Christopher E Brightling11Department of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK; 2Clinical Respiratory Management, MedImmune Ltd., Cambridge, UK; 3Global Medical Affairs, AstraZeneca, Gaithersburg, MD, USAAbstract: We hypothesized whether the reduction in eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) following treatment with benralizumab, a humanized, afucosylated, monoclonal antibody that binds to interleukin-5 receptor α, increases the airway bacterial load. Analysis of sputum samples of COPD patients participating in a Phase II trial of benralizumab indicated that sputum 16S rDNA load and Streptococcus pneumoniae were reduced following treatment with benralizumab. However, in vitro, eosinophils did not affect the killing of the common airway pathogens S. pneumoniae or Haemophilus influenzae. Thus, benralizumab may have an indirect effect upon airway bacterial load.Keywords: COPD, benralizumab, IL-5, bacterial load, S. pneumoniae, H. influenzae |
| first_indexed | 2024-12-22T20:47:59Z |
| format | Article |
| id | doaj.art-1f74c64e57f44b0bafca1cc1f6e6da6a |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-22T20:47:59Z |
| publishDate | 2019-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-1f74c64e57f44b0bafca1cc1f6e6da6a2022-12-21T18:13:10ZengDove Medical PressInternational Journal of COPD1178-20052019-06-01Volume 141177118546291Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumabGeorge LWright AMistry VSutcliffe AChachi LHaldar KRamsheh MYRichardson Mvan der Merwe RMartin UNewbold PBrightling CELeena George,1 Adam Wright,1 Vijay Mistry,1 Amanda Sutcliffe,1 Latifa Chachi,1 Koirobi Haldar,1 Mohammadali Yavari Ramsheh,1 Matthew Richardson,1 René van der Merwe,2 Ubaldo Martin,3 Paul Newbold,3 Christopher E Brightling11Department of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK; 2Clinical Respiratory Management, MedImmune Ltd., Cambridge, UK; 3Global Medical Affairs, AstraZeneca, Gaithersburg, MD, USAAbstract: We hypothesized whether the reduction in eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) following treatment with benralizumab, a humanized, afucosylated, monoclonal antibody that binds to interleukin-5 receptor α, increases the airway bacterial load. Analysis of sputum samples of COPD patients participating in a Phase II trial of benralizumab indicated that sputum 16S rDNA load and Streptococcus pneumoniae were reduced following treatment with benralizumab. However, in vitro, eosinophils did not affect the killing of the common airway pathogens S. pneumoniae or Haemophilus influenzae. Thus, benralizumab may have an indirect effect upon airway bacterial load.Keywords: COPD, benralizumab, IL-5, bacterial load, S. pneumoniae, H. influenzaehttps://www.dovepress.com/sputum-streptococcus-pneumoniae-is-reduced-in-copd-following-treatment-peer-reviewed-article-COPDCOPDbenralizumabIL-5bacterial loadS. pneumoniaeH. influenzae |
| spellingShingle | George L Wright A Mistry V Sutcliffe A Chachi L Haldar K Ramsheh MY Richardson M van der Merwe R Martin U Newbold P Brightling CE Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab International Journal of COPD COPD benralizumab IL-5 bacterial load S. pneumoniae H. influenzae |
| title | Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab |
| title_full | Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab |
| title_fullStr | Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab |
| title_full_unstemmed | Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab |
| title_short | Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab |
| title_sort | sputum streptococcus pneumoniae is reduced in copd following treatment with benralizumab |
| topic | COPD benralizumab IL-5 bacterial load S. pneumoniae H. influenzae |
| url | https://www.dovepress.com/sputum-streptococcus-pneumoniae-is-reduced-in-copd-following-treatment-peer-reviewed-article-COPD |
| work_keys_str_mv | AT georgel sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT wrighta sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT mistryv sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT sutcliffea sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT chachil sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT haldark sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT ramshehmy sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT richardsonm sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT vandermerwer sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT martinu sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT newboldp sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab AT brightlingce sputumstreptococcuspneumoniaeisreducedincopdfollowingtreatmentwithbenralizumab |